Back to Newsroom
Back to Newsroom

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of XENT, HL and RMED

Monday, 15 July 2019 11:30 AM

Kuznicki Law PLLC

Topic:
Lawsuits

CEDARHURST, NY / ACCESSWIRE / July 15, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.

Intersect ENT, Inc. (NASDAQGM: XENT)

Investors Affected : August 1, 2018 - May 6, 2019

A class action has commenced on behalf of certain shareholders in Intersect ENT, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Intersect lacked adequate reimbursement representatives to ensure physicians had access to SINUVA, Intersect’s sinus implant; (2) Intersect’s sales force would focus on ensuring reimbursement; (3) Intersect’s sales representatives were less focused on driving sales; (4) physicians were less likely to adopt Intersect’s SINUVA due to transaction costs associated with seeking reimbursement; (5) Intersect would increase staffing to address these issues; and (6) as a result of the foregoing, defendants’ positive statements about Intersect’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://kclasslaw.com/securities/intersect-ent-inc-loss-submission-form/?id=2404&from=1

Hecla Mining Company (NYSE: HL)

Investors Affected : March 19, 2018 - May 8, 2019

A class action has commenced on behalf of certain shareholders in Hecla Mining Company. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the Nevada operations were hemorrhaging cash due to a multitude of material problems identified by Defendants during Hecla’s extensive due diligence of the Nevada mines before the Class Period, and (b) as a result of these material problems, Defendants had no reasonable basis for their representations that the Nevada operations would be in a position to have positive or self-funding cash flow.

Shareholders may find more information at https://kclasslaw.com/securities/hecla-mining-company-loss-submission-form/?id=2404&from=1

Ra Medical Systems, Inc. (NYSE: RMED)

Investors Affected : stockholders that purchased Ra Medical securities pursuant and/or traceable to the Company’s September 2018 initial public offering.

A class action has commenced on behalf of certain shareholders in Ra Medical Systems, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s evaluation of sales personnel candidates was inadequate; (2) the Company’s training program for sales personnel was inadequate; (3) as a result, the Company could not reasonably assure that its newly hired sales personnel were adequately experienced; (4) as a result, the Company would suffer a shortage of qualified sales personnel; (5) the Company’s manufacturing process could not reasonably support increased catheter production; (6) as a result, the Company would suffer production delays; and (7) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://kclasslaw.com/securities/ra-medical-systems-inc-loss-submission-form/?id=2404&from=1

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 344
Cedarhurst, NY 11516
Email: [email protected]
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967

SOURCE: Kuznicki Law PLLC

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: